Replies to post #204350 on Elite Pharmaceuticals Inc (ELTP)

[lasers]

Vantrela projected a paltry $120 mil by 2020. Consider Purdue's Oxycontin at $2.7 Bil.

The Vantrela analyst obviously aware of Vantrela's easily abused features thru oral chewing and why Physicians would likely be reluctant to prescribe in his opinion.

[NASDAQ2020]

Elite has a novel pharmacologic ADT - how is society and the FDA going to tell if it actually detours abuse over an extended period of time?? They are going to have to approve it and wait for the post-marketing results to fully answer this question.

FDA will have to force people to use ADFs by removing non-ADFs.
HAL studies prove that SequestOx is an effective abuse deterrent 99% of the time for Oral, IV, Snorting, Smoking except for taking too many pills. SequestOx also could not be defeated by COMMON Solvents. There maybe a few solvents locked up and under guard in the organic chemistry lab at the University that may work.
A little dicey if you only have one pill.
Elites 2 bead ADF will be std of care for many years to come, till something better comes along.
FDA has seen the data that's why they did not waste time with an Adcom.